Skip to content
DataLookout
Menu

NCT04512716

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 28 versions: 20 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 28 words
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 12 to confirmed 11
    • Site details revised at 7 of 7 sites
  2. Notable Primary and study completion dates: Jan 2026 to Jan 2027v26
  3. Notable Enrollment target: 6 to 12v25
  4. Study Identification, Study Status, Oversight, Contacts/Locationsv24
  5. Study Identification, Study Status, Oversightv23
Show 14 earlier versionsHide 14 earlier versions
  1. Notable Primary and study completion dates: Jan 2025 to Jan 2026v22
  2. Study Identification, Study Status, Oversightv21
  3. Minor Collaborators shortened, about 2 wordsv15
  4. Notable Primary and study completion dates: Jan 2024 to Jan 2025
    • Study sites: 1 to 7
    • Eligibility criteria shortened, about 1 word
    v14
  5. Notable Eligibility criteria expanded, about 44 wordsv13
  6. Notable Primary and study completion dates: Jan 2023 to Jan 2024v12
  7. Notable Eligibility criteria expanded, about 144 wordsv10
  8. Notable Primary and study completion dates: Jan 2022 to Jan 2023v9
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 6 words
    • Start date changed from estimate of Feb 2021 to Feb 2, 2021
    • Site details revised
    v7
  10. Minor Start date: Jan 2021 to Feb 2021v6
  11. Notable Start date: Oct 2020 to Jan 2021
    • Primary and study completion dates: Aug 2021 to Jan 2022
    v5
  12. Minor Start date: Sep 2020 to Oct 2020v4
  13. Notable Eligibility criteria expanded, about 2 words
    • Start date: Aug 31, 2020 to Sep 2020
    v3
  14. Minor Study title shortened, about 1 wordv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-limiting toxicities and maximum tolerated dose of 131-I apamistamab, when given in combination with 19-28z CAR T-cells for treatment of relapsed or refractory B-cell ALL or DLBCL
Timeframe: 30 days after treatment

Arms and interventions

B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell LymExperimental

Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma

Drugs: 131-I Apamistamab

Biologicals: CAR T-cell

Sites

7 sites in 1 country